Update de-_mystifying__r__programming_in__clinical__trials.qmd

Author: NavitasLifeSciences

posts/2024-04-15_de-_mystifying__.../de-_mystifying__r__programming_in__clinical__trials.qmd

@@ -74,6 +74,9 @@ to replace SAS® with R, use both, or explore other alternatives like
 Python. Instead of adopting an either-or scenario, leveraging the
 strengths of each programming language for specific Data Science
 problems is recommended, recognizing that one size does not fit all.
+Despite the challenges early adopters of R have faced in regulatory compliance,
+there have been notable successes that highlight the benefits and potential of 
+using R in regulated industries.
 Early adopters of R have faced challenges, with regulatory compliance
 for R packages being a common issue.
 
@@ -100,7 +103,7 @@ The pharmaceutical industry has witnessed the emergence of various R
 packages tailored for Clinical Trial reporting. Examples include
 `{rtables}` for creating tables for reporting clinical trials,
 `{admiral}` for CDISC ADaM, `{pkglite}` to support eSubmission, and many
-others. These packages cater to different aspects of clinical trial data
+others. Pharmaverse packages cater to different aspects of clinical trial data
 analysis, showcasing the versatility of R in this domain.
 
 This article talks more about use of R in clinical trials and how this
@@ -150,24 +153,14 @@ approach.
 
 Ensuring data quality, scientific integrity, and regulatory compliance
 through risk assessment frameworks, validation, and documentation are
-imperative in this dynamic landscape. The pharmaceutical industry's
-journey toward embracing R reflects the broader trend of industries
-recognizing the value and potential of open-source tools in addressing
-complex challenges.
+imperative in this dynamic landscape. Pharmaverse is also actively steering
+the pharmaceutical industry's path by pioneering connections and advocating
+for R, thus exemplifying the broader trend of industries acknowledging the 
+value and potential of open-source tools in tackling complex challenges.
 
 ![Leveraging the Right Tools](RightTool.png){fig-align="center"}
 
-## Author
-
-Venkatesan Balu is the Associate Director, Global Data Sciences, Navitas
-Life Sciences with 15+ years of experience in the Biostatistics domain,
-and in Phase I to Phase IV Clinical Trials across various therapeutic
-areas, BABE and PK studies. He has invaluable expertise in providing
-inputs to study design, sample size, SAP, outlier evaluation, interim
-analysis, complex statistical evaluation & model selection, and
-regulatory requirement. He is a technical leader in drug development
-strategy, adaptive design, portfolio optimization, and decision-making
-in clinical trials.
+
 
 <!--------------- appendices go here ----------------->